Literature DB >> 8912354

Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase.

L Cook1, J G Burdon, S Brenton, K R Knight, E D Janus.   

Abstract

Patients homozygous for the Z allele of alpha-1-antitrypsin (alpha 1AT) have very low serum levels and are predisposed to emphysema. There have also been reports of emphysema being associated with the heterozygous phenotype FZ. To investigate whether F alpha 1AT was dysfunctional, the inhibitory activity of F alpha 1AT against human neutrophil elastase (HNE) was compared with that of common alpha 1AT phenotypes. Time-dependent inhibition of HNE by alpha 1AT was used to calculate the association rate constant (k assoc) for M, MZ, FM, FZ, F (partially purified from FZ or FS), Z and S alpha 1AT phenotypes in human sera. The results for k assoc at 25 degrees C were 9.1 (SD 0.9), 9.7 (SD 0.9), 8.0 (SD 0.8), 4.0 (SD 0.4), 4.2 (SD 0.8), 5.1 (SD 0.6) and 8.6 (SD 0.6) x 10(6) M-1s-1 respectively. F was found to have reduced activity much like that of Z, the alpha 1AT most commonly associated with emphysema. MZ (low risk for disease) and FZ heterozygotes had similar intermediate alpha 1AT levels. However the in vivo inhibition time for FZ was almost three times longer than for MZ, indicating greater exposure to proteolytic damage from free elastase for FZ than MZ individuals. In conclusion, F alpha 1AT is expressed in serum at low normal levels but is dysfunctional in its ability to inhibit HNE. Individuals who coinherit the F and a deficiency allele such as Z or Null, are likely to have a high risk for the development of emphysema. The disease risk for F homozygotes remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912354     DOI: 10.1080/00313029600169074

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  7 in total

1.  A challenging diagnosis of alpha-1-antitrypsin deficiency: identification of a patient with a novel F/Null phenotype.

Authors:  Michael R Ringenbach; Erin Banta; Melissa R Snyder; Timothy J Craig; Faoud T Ishmael
Journal:  Allergy Asthma Clin Immunol       Date:  2011-11-13       Impact factor: 3.406

2.  α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.

Authors:  Nicola J Sinden; Michael J Baker; David J Smith; Jan-Ulrich Kreft; Timothy R Dafforn; Robert A Stockley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-15       Impact factor: 5.464

Review 3.  The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.

Authors:  Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

4.  The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote.

Authors:  Nicola Jane Sinden; Firas Koura; Robert Andrew Stockley
Journal:  BMC Pulm Med       Date:  2014-08-07       Impact factor: 3.317

5.  Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population.

Authors:  Mattia Laffranchi; Emma L K Elliston; Fabrizio Gangemi; Romina Berardelli; David A Lomas; James A Irving; Annamaria Fra
Journal:  PLoS One       Date:  2019-01-11       Impact factor: 3.752

Review 6.  Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.

Authors:  Susana Seixas; Patricia Isabel Marques
Journal:  Appl Clin Genet       Date:  2021-03-22

7.  In plain sight: the role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics.

Authors:  Kasopefoluwa Y Oguntuyo; Christian S Stevens; Mohammed Na Siddiquey; Robert M Schilke; Matthew D Woolard; Hongbo Zhang; Joshua A Acklin; Satoshi Ikegame; Chuan-Tien Hung; Jean K Lim; Robert W Cross; Thomas W Geisbert; Stanimir S Ivanov; Jeremy P Kamil; Benhur Lee
Journal:  bioRxiv       Date:  2020-08-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.